Sonoma Pharmaceuticals Announces Licensing of Antimicrobial Hypochlorous Acid Solution for Management of Blepharitis in the Spanish/Portuguese Markets to Brill Pharma, S.L.
26 sept. 2018 07h05 HE
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty pharmaceutical company that develops and markets unique and effective solutions for the...
Sonoma Pharmaceuticals Appoints Phillipe Weigerstorfer to Board of Directors
19 sept. 2018 07h05 HE
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., Sept. 19, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), today announced the appointment of Philippe Weigerstorfer to the company’s board of directors. ...
Sonoma Pharmaceuticals Announces Results from Study of Sonoma’s Performance-Stabilized HOCl™ (Hypochlorous Acid) in Management of Acne Vulgaris
28 août 2018 07h05 HE
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), today announced that results from a study into the use of the company’s proprietary high-strength...
Sonoma Pharmaceuticals Reports First Quarter FY 2019 Financial Results
08 août 2018 16h05 HE
|
Sonoma Pharmaceuticals, Inc.
Total Revenue up 20% over March 2018 Quarter Total Revenue up 14% over June 2017 Quarter Conference Call Begins at 4:30pm EDT Today PETALUMA, Calif., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Sonoma...
Sonoma Pharmaceuticals Announces First Quarter FY 2019 Financial Results and Conference Call
25 juil. 2018 07h05 HE
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., July 25, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA) today announced that financial results for its fiscal year 2019 first quarter, ended June 30, 2018,...
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2018 Financial Results
13 juin 2018 16h05 HE
|
Sonoma Pharmaceuticals, Inc.
Strong Annual Year-Over-Year Growth in Revenue of 30%$10 Million in Cash as of March 31, 2018 Conference Call Begins at 4:30pm EDT Today PETALUMA, Calif., June 13, 2018 (GLOBE NEWSWIRE) -- Sonoma...
U.SK, dermatology arm of Brazilian NC Group, and Sonoma Pharmaceuticals Enter into License Agreement for Exclusive Rights to Sonoma’s Dermatology Products in Brazil
05 juin 2018 07h05 HE
|
Sonoma Pharmaceuticals, Inc.
SAO PAULO, Brazil and PETALUMA, Calif., June 05, 2018 (GLOBE NEWSWIRE) -- U.SK Dermatology, the dermatology arm of NC Group, which besides other businesses is the largest pharmaceutical organization...
Sonoma Pharmaceuticals Announces Fiscal Year/Fourth Quarter 2018 Financial Results and Conference Call
31 mai 2018 07h05 HE
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., May 31, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), today announced that financial results for its fiscal fourth quarter 2018, ended March 31, 2018, will...
Sonoma Pharmaceuticals Names Marc Umscheid Chief Operating Officer
08 mai 2018 07h00 HE
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a specialty pharmaceutical company that develops and markets unique and effective dermatological...
Sonoma Pharmaceuticals Receives Four New UAE Regulatory Approvals that Include Acne and Anti-Fungal Products
17 avr. 2018 07h04 HE
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., April 17, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective...